Pharma doesn’t just defend patents anymore—it builds a stack.
In a world where “one patent” is increasingly easy to challenge, companies are getting more sophisticated about how they delay generic entry. The playbook highlighted in DrugPatentWatch’s an…

India’s “drug patent clock” isn’t what most people think. Here’s the real timeline that decides who wins—and who gets delayed.
If you work in pharma—whether you’re a brand team, a generic manufacturer, a policy stakeholder, or an investor—you’ve probab…

The Generic Drug Race Is No Longer Just About Patents—It’s About Timing, Leverage, and the 180-Day Clock
In the U.S. pharmaceutical market, the biggest battles aren’t always fought in courtrooms. They’re fought in filings, deadlines, and procedural str…

Biopharma’s next competitive edge isn’t just science—it’s timing.
In Europe, the window between “patent still active” and “generic entry imminent” is where deals are won—or lost. Yet most commercial and market-access teams treat tender readiness as a…

Biopharma talent is moving—fast—and the next stop isn’t just “more biosimilars.” It’s the legal chessboard behind them.
If you want a real-time read on where the industry is headed, don’t start with pipeline decks. Start with patent wars. A new analysi…

Specialty pharmacy contracts don’t wait for patent cliffs. Neither should your go-to-market.
In biopharma, the calendar is the quiet killer.
A patent expiration isn’t just a legal milestone—it’s a commercial event that can compress margins, reorder for…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams don’t buy “a drug.” They buy a lifecycle.
That’s the uncomfortable truth behind the real price of medicines—and why many organizations still underestimate what they’re actually paying for when they sign a contract.
In a world w…